Myovant Sciences

$14.40 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Myovant Sciences

Myovant Sciences Ltd, is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for the treatment women’s health and endocrine diseases. Its lead product candidate is Relugolix, which is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone (LH), and follicle-stimulating hormone (FSH), thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is also advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer. The Company is developing MVT-602, an oligopeptide kisspeptin agonist, for the treatment of female infertility.

Stock Analysis

last close $14.73
1-mo return -6.4%
3-mo return -27.3%
avg daily vol. 721.51T
52-week high 27.43
52-week low 13.14
market cap. $1.4B
forward pe -
annual div. -
roe -622%
ltg forecast -
dividend yield -
annual rev. $145M
inst own. 38.1%
baraka

Subscribe now for daily local and international financial news

Subscribe